Researchers conducted a post hoc, retrospective, cross-sectional analysis of 182 patients with recurrent prostate cancer ...

Secondary outcome-measures on quality-of-life (QoL) and treatment satisfaction are reported. Methods Patients, aged <68 yrs, with adenocarcinoma of the prostate ... placebo after OLT were not ...

Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic disease missed by conventional imaging, investigators report.

A 62-year-old man with a parastomal hernia at the site of a urinary conduit and symptoms of urinary obstruction lasting ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

After skin cancer, prostate cancer is the most common cancer in men in the US. For the men who have beat prostate cancer once, 20 to 30 percent will show signs of recurrence after the five-year mark ...

Q2 2025 Earnings Call Transcript January 8, 2025 AngioDynamics, Inc. beats earnings expectations. Reported EPS is $-0.04, ...

AngioDynamics' NanoKnife FDA clearance boosts its potential in cancer treatment. Read why ANGO stock is a buy with its growth ...

Q2 2025 Earnings Conference Call January 8, 2025 8:00 AM ETCompany ParticipantsJim Clemmer - President and Chief ...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, ...

After skin cancer, prostate cancer is the most common cancer in men in the US. For the men who have beat prostate cancer once ...

Stephen Trowbridge; Chief Financial Officer, Executive Vice President; AngioDynamics Inc Good morning and welcome to the AngioDynamics fiscal year 2025 second quarter earnings call at this time.